Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment
of metastatic and advanced NSCLC, but its application in neoadjuvant setting has not been
well established. Results from a pilot clinical study reported the safety and feasibility of
neoadjuvant PD-1 blockade. There are several neoadjuvant immunotherapy (NEOSTAR, LCMC3,
NADIM, IMpower131) ongoing, and the preliminary results are reported in 2019 American Society
of Clinical Oncology, which show promising therapeutic prospect. However, the therapeutic
response rate (major pathologic response [MPR]) are not so good (20% - 45%) for PD-1
inhibitor monotherapy. To improve the therapeutic response, the investigators design a
multiple-canter, open-label, phase II trial for stage II-IIIA resectable NSCLC. The
participants will receive neoadjuvant PD-1 inhibitor (camrelizumab) combined with
antiangiogenic drug (apatinib) or platinum-based chemotherapy.